Compare Vertex Pharmaceuticals Incorporated (VRTX) vs Western Alliance Bancorporation (WAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vertex Pharmaceuticals Incorporated vs Western Alliance Bancorporation — how do they compare? Vertex Pharmaceuticals Incorporated trades at $481.47 (market cap $121.95B), while Western Alliance Bancorporation trades at $79.8 (market cap $8.84B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 13.8× Western Alliance Bancorporation's market cap, and Western Alliance Bancorporation pays a 2.07% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| VRTX | WAL | |
|---|---|---|
Market Cap | $121.95B | $8.84B |
Sector | Health | Financials |
52-Week High | $529.59 | $96.08 |
52-Week Low | $366.54 | $66.70 |
Enterprise Value | $116.69B | — |
Dividend Yield | — | 2.07% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →About Western Alliance Bancorporation
Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →
